About Land Therapeutics
Land Therapeutics develops a treatment for people with sickle cell disease. Its goal is an affordable gene therapy delivered inside the body.
Land Therapeutics uses a Charlestown, Massachusetts address. Tony Ho is CEO, and Rob Hopfner is a director.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | Jan 7, 2025amended Oct 21, 2026 | $17,511,614of $92.1M target | 12 | $1.4M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Land Therapeutics
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Oct 2, 2025 | Grant | $4,997,221 | Gates Foundation (lead) | Gates Foundation grant page ↗ |
Why Investors Backed Land Therapeutics
Land Therapeutics is developing gene therapy for sickle cell disease. It plans to deliver the treatment inside the body. Affordability is part of the development goal.
Progress so far
A $4,997,221 grant was committed in October 2025. The award covers 22 months. The grant names Cambridge, Massachusetts, as the grantee location.
Who backs it
The Gates Foundation provides the funding through its Global Health division. It classifies the award under Create Novel Technology Platform Capabilities. The stated service region is global.
We wrote this summary from public statements by Land Therapeutics and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Land Therapeutics's Form D filed Oct 21, 2026.